Browsing Pharmacology and Toxicology by Submit Date
Now showing items 61-80 of 114
-
Obesity in a model of haploinsufficiency uncovers a causal role for lipid-derived aldehydes in human metabolic disease and cardiomyopathy
(2015-04)Lipid peroxides and their reactive aldehyde derivatives (LPPs) have been linked to obesity-related pathologies, but whether they have a causal role has remained unclear. Glutathione peroxidase 4 (GPx4) is a selenoenzyme ... -
Interactions of a Dopamine D Receptor Agonist with Glutamate NMDA Receptor Antagonists on the Volitional Consumption of Ethanol by the mHEP Rat
(2013-03)Stimulation of the dopamine D1 receptor is reported to cause the phosphorylation of DARPP-32 at the thre34 position and activates the protein. If intracellular Ca2+ is increased, such as after activation of the glutamate ... -
Multi-walled carbon nanotube instillation impairs pulmonary function in C57BL/6 mice
(2011)Background Multi-walled carbon nanotubes (MWCNTs) are widely used in many disciplines due to their unique physical and chemical properties. Therefore, some concerns about the possible human health and environmental ... -
Environmental risk factors for autism
(2010-04)Autism is a devastating childhood condition that has emerged as an increasing social concern just as it has increased in prevalence in recent decades. Autism and the broader category of autism spectrum disorders are among ... -
Interlaboratory Evaluation of Rodent Pulmonary Responses to Engineered Nanomaterials: The NIEHS Nano GO Consortium
(2013-05)Background: Engineered nanomaterials (ENMs) have potential benefits, but they also present safety concerns for human health. Interlaboratory studies in rodents using standardized protocols are needed to assess ENM ... -
Brain stem adenosine receptors modulate centrally mediated hypotensive responses in conscious rats: A review
(2014-12)Abbreviations: A2A, adenosine subtype A2A receptor; A1, adenosine subtype A1 receptor; ABC, avidin biotin complex; ABD rat, aortic barodenervated rat; α2 AR, alpha 2 adrenergic receptor; αMNE, alpha methyl norepinephrine; ... -
Association of Perfluoroalkyl Substances, Bone Mineral Density, and Osteoporosis in the U.S. Population in NHANES 2009-2010
(2015-06)Background Perfluoroalkyl substances (PFASs), including perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexane sulfonic acid (PFHxS), and perfluorononanoic acid (PFNA), are detectable in the ... -
Identification of Factors Associated with the Development and Decay of Heterologous Tolerance to Morphine in the Guinea Pig
(East Carolina University, 2016-05-03)It is believed that the heterologous tolerance that develops upon chronic exposure to morphine is the result of adaptive changes in the cellular signaling pathways associated with the [mu] opioid receptor. Proposed adaptive ... -
Central GPR109A Mediates Neuronal Oxidative Stress and Pressor Response in Conscious Rats
(East Carolina University, 2016-05-03)The primary goal of this study was to characterize the role of GPR109A in the rostral ventrolateral medulla (RVLM) in blood pressure (BP) regulation and to elucidate the mechanisms involved in the hypertensive response ... -
A composition comprising nerve growth factor and 2-amino-1,1,3-tricyano-1-propene useful for the induction, stimulation, and maintenance of nerve growth, and methods of potentiating choline O-acetyltransferase and tyrosine hydroxylase by 2-amino-1,1,3-tricyano-1-propene are disclosed.
(1997-09-09)A composition comprising nerve growth factor and 2-amino-1,1,3-tricyano-1-propene useful for the induction, stimulation, and maintenance of nerve growth, and methods of potentiating choline O-acetyltransferase and tyrosine ... -
Method for nerve growth induction
(1993-03-16)A composition comprising nerve growth factor and 2-amino-1,1,3-tricyano-1-propene useful for the induction, stimulation, and maintenance of nerve growth, and methods of potentiating choline O-acetyltransferase and tyrosine ... -
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
(2004-11-30)A pharmaceutical composition effective for preventing and alleviating bronchoconstriction, lung allergy(ies) and inflammation comprises a surfactant and an oligonucleotide anti-sense to an adenosine receptor gene, flanking ... -
Low adenosine agent, composition, kit and method for treatment of airway disease
(1999-11-30)An oligonucleotide which is antisense to a mRNA encoding a polypeptide involved in airway disease(s) contains up to three adenosines per every 21 nucleotide a method of treating airway disease in a subject in need of such ... -
Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
(1996-06-18)A method of combatting cancer in a subject comprising administering to said subject dehydroepiandrosterone (DHEA) or an analog thereof in an amount effective to combat cancer is disclosed in which heart failure induced by ... -
Agent and method for treating disorders associated with cytidine deaminase or deoxycytidine deaminase overexpression
(2000-10-24)An agent of the chemical formula C.sub.7 N.sub.3 H.sub.8 O.sub.2 R.sup.1 R.sup.2 XX.sup.1, wherein X and X.sup.1 are each independently C or N but not simultaneously, R.sup.1 is lower alkyl, alkenyl or alkynyl, halogen or ... -
Satiety inducing composition comprising Neuropeptide Y analogues and methods of inducing satiety and treating a disease or condition associated with it
(2002-07-30)Satiety inducing composition comprises Neuropeptide Y analogues which are effective for inducing satiety and for treating diseases and conditions associated with a lacking of, or having lowered, satiety. -
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
(2002-08-13)A composition, device, kit and method for countering or diagnosing cytidine deaminase or deoxycytidine deaminase over-expression or a disorder associated with it, or an increase in number or toxicity of pro-inflammatory ... -
Method of treating adenosine depletion
(1997-08-26)A method of treating adenosine depletion in a subject in need of such treatment is disclosed. The method comprises administering to the subject folinic acid or a pharmaceutically acceptable salt thereof in an amount effective ... -
Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone
(2000-07-11)A method and composition for reducing adenosine levels comprises administering a dehydroepiandrosterone, and optionally a ubiquinone.